Drug intelligence / Profile preview

K128

Development stage: Unknown
Lead developer: Amneal Pharmaceuticals

Overview

K128 is a pharmaceutical product that is part of the pipeline of Kashiv Specialty Pharmaceuticals (KSP), a company acquired by Amneal Pharmaceuticals LLC. KSP's pipeline is known to include 505(b)(2) branded products, primarily targeting neurology and endocrinology, as well as complex generics and innovative drug delivery platforms. However, specific details regarding the mechanism of action, primary indication, or development phase of K128 are not provided in the available information.

Beyond the preview

Go deeper on K128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K128.

Explore the full profile